Observational studyCancer medicine2026
Prevalence and Determinants of Depression, Anxiety, and Quality of Life in Patients With Breast Cancer in Saudi Arabia: A Focus on Adjuvant Pharmacotherapy.
Observational study in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimWhile psychological distress is a well-documented concern among cancer patients, the prevalence and severity of depression and anxiety in breast cancer patients in Saudi Arabia remain insufficiently explored. This study aimed to evaluate depression, anxiety, and quality of life (QoL) among patients with breast cancer undergoing adjuvant pharmacotherapy in Saudi Arabia.
methodsA cross-sectional observational study was conducted among patients with breast cancer receiving adjuvant therapy. Data were collected using the Patient Health Questionnaire-9 (PHQ-9) for depression, the Generalized Anxiety Disorder-7 (GAD-7) for anxiety, and the Quality-of-Life Questionnaire-C30 (QLQ-C30) for QoL assessment.
resultsAmong 246 patients, the most prevalent cancer subtype was hormone receptor-positive (65.0%), followed by human epidermal growth factor receptor 2 (HER2)-positive (13.4%), triple-negative (11.0%), and HER2/hormone receptor-positive (10.6%). Trastuzumab (20.3%) and pembrolizumab (11.0%) were the most commonly administered biological therapies, while letrozole (45.5%) and tamoxifen (22.8%) were the most used hormonal agents. Notably, 48.4% of patients received chemotherapy. The mean ± standard deviation (SD) of PHQ-9 score was 12.87 ± 7.63, and the mean ± SD of GAD-7 score was 9.55 ± 5.53, with clinical significant depression and anxiety of 54.1% and 49.6%, respectively. The mean ± SD of the QLQ-C30 score was 58.84 ± 24.98. Multivariate analysis revealed that chemotherapy and the number of cycles were significantly associated with higher levels of depression and anxiety. Quality of life was negatively impacted by chemotherapy, endocrine therapy, and the number of treatment cycles.
conclusionDepression, anxiety, and reduced QoL are prevalent among breast cancer patients undergoing treatment in Saudi Arabia. Chemotherapy and endocrine therapy contribute significantly to psychological distress, and diminished QoL.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.